Mathematics
Dose Finding
100%
Toxicity
76%
Dose
73%
Design
70%
Drugs
45%
Clinical Trials
35%
Efficacy
33%
Maximum Tolerated Dose
23%
Phase I Trial
22%
Interval
19%
Continual Reassessment Method
19%
Covariance matrix
18%
High-dimensional
18%
Safety
15%
Simulation Study
14%
Oncology
14%
Performance
14%
Optimise
13%
Schedule
12%
Interval Probability
12%
Model-based Design
11%
Bayesian Optimal Design
9%
Posterior Probability
9%
Control Design
9%
Sample Size Re-estimation
9%
Sample Size
8%
Scenarios
8%
Exact Inference
8%
Decision Making
8%
Model
8%
Hypothesis Testing
8%
Subgroup
8%
Group Sequential
8%
Monitoring
8%
Randomized Clinical Trial
7%
Two-sample Test
7%
Spectral Distribution
7%
Framework
7%
Missing Data
7%
Random Matrix Theory
7%
Operating Characteristics
7%
Receiver Operating Characteristic Curve
7%
Relative Efficiency
7%
Correlation Matrix
7%
Quantify
6%
Bootstrap Method
6%
Missing at Random
6%
Demonstrate
6%
Autocorrelation
6%
Singular Values
6%
Medicine & Life Sciences
Maximum Tolerated Dose
35%
Phase II Clinical Trials
26%
Sample Size
25%
Clinical Trials, Phase I
22%
Immunotherapy
20%
Bayes Theorem
16%
Clinical Trials
15%
Lymphedema
14%
Safety
12%
Software
11%
Drug Development
11%
Non-Small Cell Lung Carcinoma
11%
Lymphatic Abnormalities
10%
Breast Cancer Lymphedema
9%
Agammaglobulinaemia Tyrosine Kinase
8%
Decision Making
8%
BK Virus
8%
Biosimilar Pharmaceuticals
8%
Nivolumab
8%
Standard of Care
8%
Therapeutics
8%
Azacitidine
8%
Breast Neoplasms
8%
Mantle-Cell Lymphoma
8%
Neoplasms
7%
Troponin T
7%
Cystitis
7%
Prostatic Neoplasms
7%
National Cancer Institute (U.S.)
7%
Cardiotoxicity
6%
Cytotoxic T-Lymphocytes
6%
Chemoradiotherapy
6%
Appointments and Schedules
6%
T-Cell Antigen Receptor
6%
Head and Neck Neoplasms
6%
Pharmaceutical Preparations
6%
Random Allocation
6%
Chimeric Antigen Receptors
5%
Calibration
5%
Statistical Models
5%
Lung Neoplasms
5%
Radiotherapy
5%
Suspensions
5%
Survival
5%
ROC Curve
5%
PCI 32765
5%
Coronary Vessels
5%